Anthrax Vaccine Market: By Vaccine Type (Live Vaccines, Cell free PA Vaccines), By End User (Hospitals, Clinics, Vaccination Centers, Others), and Geography    

Anthrax Vaccine Market size was valued at USD 10.67 billion in 2023 and is poised to reach at  USD 11.83 billion in 2030, and is expected to grow at a CAGR of 7.5% from 2024-2030. Anthrax is a severe infectious disease caused by Bacillus anthracis. Signs and symptoms include vomiting, nausea, abdominal pain, headache, loss of appetite, fever, severe bloody diarrhea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors for anthrax include injection of illegal animal drugs, handling animal skins, and working in veterinary medicine, especially dealing with livestock. The market is driven by the growing threat of communicable diseases such as anthrax across the globe.

Moreover, the cost-effectiveness of immunizations, new funding opportunities from government, donors, and research foundations, and advances in research and manufacturing technologies are expected to drive market revenue growth of the anthrax vaccine over a forecast period. In addition, the availability of large target populations in emerging markets drives the growth of the anthrax vaccine market. However, lack of awareness, the high cost of the vaccine in underdeveloped economies, lack of availability and affordability, and stringent regulations are the factors that are restraining the growth of the market. Anthrax infections are predominantly categorized into cutaneous (95%), pulmonary (5%), and gastrointestinal (1%) origins. Given these risks, anthrax vaccination emerges as a crucial preventive measure to curb the spread of infection. Notably, a study published in NCBI in 2023 highlighted that vaccination campaigns targeting anthrax in both humans and animals have significantly reduced the incidence of the disease in developed countries